OR WAIT null SECS
April 06, 2023
New facility—located on company’s Pennsylvania site—is part of three-part manufacturing contract with BARDA.
April 05, 2023
Rise in value attributed to the ongoing decentralization of pharmacies.
March 13, 2023
Q&A explores new opportunities to strengthen supply chain resilience—and build on the lessons learned.
March 10, 2023
Project addresses customer demand in GMP-powered advanced therapeutics.
March 09, 2023
New site is expected to complement CDMO’s commercial production experience.
March 08, 2023
Acquisition expands company’s eCTD submission capabilities.
March 02, 2023
Hoping to accelerate the drug delivery process, production is expected to begin as early as 2025.
Following numerous successful trial runs, vaccine production is expected to reach 700 million.
March 01, 2023
Expansion expected to increase global capacity by 75%.
Joint venture revolves around around the use of raw materials for the development—and ultimately commercialization—of therapies.